达格列净 T2389

Product Introduction
Bioactivity


英文名: Dapagliflozin

描述: Dapagliflozin (BMS-512148) 竞争性的葡萄糖协同转运蛋白2 (SGLT2) 抑制剂，可促进尿液中葡萄糖的排泄，在糖尿病 (DM) 研究中具有价值。Dapagliflozin 诱导 HIF1表达并减轻肾脏 IR 损伤。

细胞实验: To perform the cell survival assay, cells are collected after 24 h incubation with vehicle or dapagliflozin pretreatment in 30-min ischemia and surviving cells are counted with Trypan blue staining. The percentage survival is determined by quantization of the relative viable number of treated cells divided by the viable number of untreated cells.

体外活性: 在体外代谢通路中,Dapagliflozin能够参与糖脂化,羟乙基化,脱乙基作用。在大鼠,犬,猴,人类血清中,Dapagliflozin（10 μM ）能够稳定发挥作用。在无蛋白buffer中,Dapagliflozin（20 μM）能够选择性地作用于GLUT转运蛋白

体内活性: 在高血糖链脲佐菌素大鼠中,口服 Dapagliflozin（0.1 mg/kg）能够降低血糖水平.在Zucker糖尿病肥胖大鼠中,Dapagliflozin对于肝脏和肾脏表现出良好的安全性,能够降低葡萄糖水平.

存储条件: store at low temperature,store under nitrogen,keep away from moisturePowder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: Ethanol : 14 mg/mL (34.2 mM)
5% DMSO+95% Saline : 3.8 mg/mL (9.29 mM, suspension)
H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 45 mg/mL (110.06 mM)


关键字: BMS512148 | Sodium-dependent glucose cotransporters | SGLT | inhibit | BMS 512148 | Inhibitor | Dapagliflozin

相关产品: Velagliflozin | Kushenol C | T-1095 | Mizagliflozin | HSK0935 | Sergliflozin etabonate | Picraline | SGLT inhibitor-1 | Bexagliflozin | IRAK inhibitor 4 trans

相关库: Drug Repurposing Compound Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Inhibitor Library | Anti-Cancer Clinical Compound Library | GPCR Compound Library | Highly Selective Inhibitor Library | Anti-Cancer Approved Drug Library | EMA Approved Drug Library | Metabolism Compound Library

达格列净 T2389信息由TargetMol中国为您提供，如您想了解更多关于达格列净 T2389报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途